= Solution
\b[Monoamine signalling contributes to mood regulation and to the actions of several antidepressants, but a universal “low transmitter causes depression” account is not established.] Three propositions must be separated: a drug changes a molecular target; that change helps produce improvement; and the untreated disorder was caused by an opposite abnormality. Evidence for one proposition does not logically establish the next.
The <monoamine hypothesis of depression> developed from pharmacology. <Monoamine oxidase> inhibition reduces transmitter metabolism, while some tricyclic antidepressants inhibit transmitter reuptake; <SSRI> principally inhibit <serotonin> reuptake. <Norepinephrine>, <serotonin> and <dopamine> are distinct <monoamines>, acting through different receptors and pathways. The historical catecholamine proposal emphasized <norepinephrine> and already acknowledged the limitations of extrapolating from drug effects to disease mechanisms. Treating every low affective state as depletion of a single interchangeable brain substance is a substantially stronger claim.<The catecholamine hypothesis of affective disorders: a review of supporting evidence by Joseph J. Schildkraut>[1965 abstract and pp. 509–522: proposed catecholamine account and explicit limits on pharmacological extrapolation]{ref}
Drug efficacy supplies evidence that manipulating these systems can matter. A 2018 <network meta-analysis> synthesized 522 double-blind trials in adults with <major depressive disorder> and found each included antidepressant more efficacious than placebo on its response outcome. This is evidence synthesis, not a direct assay of patients' transmitter levels. Average effects, trial selection, <publication bias>, blinding and symptom-scale outcomes limit interpretation, and not every patient benefits. Even a perfectly demonstrated effect would show that an intervention can change a pathological state, not that it reverses its original cause. A downstream compensatory mechanism can be therapeutically useful without being the initiating lesion.<Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder by Andrea Cipriani and others>[Methods, Findings and Discussion: acute adult trials, response outcome and limitations]{ref}
Measuring the proposed deficiency is itself difficult. Peripheral <serotonin> is not a direct measurement of release at a particular central <synapse>. Metabolites combine synthesis, release, reuptake and degradation; receptor or transporter imaging is not simply a concentration gauge. A difference observed after illness onset might be causal, compensatory, treatment-related or associated with <physiological stress>. Establishing a general deficiency would require convergent measures in appropriate untreated populations, temporal precedence and a relationship to well-defined symptoms, not merely one group-average biomarker.
Precursor depletion supplies a more informative intervention. In a double-blind crossover study, patients in antidepressant-induced remission underwent acute <tryptophan> depletion and a control condition. Fourteen of 21 experienced a transient depressive relapse after depletion, whereas control testing did not produce significant behavioural effects. This supports dependence of some maintained remissions on <serotonin> precursor availability. It does not show that all untreated depressed patients began with low <serotonin>, that depletion is sufficient to generate the full syndrome in everyone, or that <norepinephrine> and <dopamine> are irrelevant. The selected, previously treated sample is central to the causal question actually tested.<Serotonin function and the mechanism of antidepressant action by Pedro L. Delgado and others>[Abstract and pp. 411–418: remitted sample, crossover control and 14/21 transient relapses]{ref}
Time course also challenges a simple replenishment story. Initial transporter inhibition can occur before substantial clinical improvement. That discrepancy motivates slower receptor, circuit, learning and plasticity changes; it does not imply that early drug effects are absent. In a randomized placebo-controlled experiment, an acute dose of a norepinephrine reuptake inhibitor changed positive emotional processing in depressed participants before subjective mood or anxiety changed. Facial-expression judgments and emotionally valenced categorization and recall supplied behavioural readouts. These observations support an <affective processing bias> account: altered experience processing could accumulate into mood change. They do not establish that the measured early shift mediates every later clinical response.<Effect of acute antidepressant administration on negative affective bias in depressed patients by Catherine J. Harmer and others>[Abstract; Methods and Results, pp. 1178–1184: randomized emotional-processing battery before mood change]{ref}
Plasticity offers another candidate bridge between early pharmacology and delayed behaviour. In mice, preventing antidepressant-associated <adult hippocampal neurogenesis> blocked behavioural effects in particular experimental assays. The evidence included genetic and localized irradiation approaches. It supplies a mechanistic dependency within that model, rather than merely a <correlation> between a drug and cell proliferation. However, the assays are not human <major depressive disorder>, the interventions can have additional effects, and necessity for one behavioural endpoint does not establish either sufficiency or a universal human mechanism.<Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants by Luca Santarelli and others>[Abstract and pp. 805–809: interference with neurogenesis and model-specific behavioural effects]{ref}
These alternatives refine rather than simply discard monoaminergic pharmacology. <Serotonin> or <norepinephrine> could regulate plasticity and learning within distributed <neural circuits>; baseline concentrations need not be uniformly low. Receptor sensitivity, pathway-specific activity and environmental experience could determine the effect of an intervention. Conversely, observing altered <dopamine>-related motivation would not prove that all <anhedonia>, cognitive slowing and sadness have one cause. <Major depressive disorder> groups multiple symptom patterns, so a mechanism associated with one dimension can be diluted or misleading when treated as a universal disease explanation.
The strongest conclusion available at the examination date is therefore conditional. Particular <monoamine> manipulations can alter affective processing and symptoms, and some treatment responses depend on monoaminergic function. The evidence does not identify a single brain-wide deficit that is necessary and sufficient for human depression. A useful successor account specifies transmitter, receptor, circuit, time scale and symptom, and tests how biological changes interact with learning and environment. This evaluation concerns explanatory evidence, not a recommendation to start, stop or choose a medication.
Back to article page
